NASDAQ:ADMS

Adamas Pharmaceuticals, Inc Earning Date

USA |NASDAQ |USD

ADMS Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Nov 3, 2021 Sep 2021 $-0.22 $-0.27 $-0.42
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Nov 3, 2021 Sep 2021 $24.77M $21.97M $20.18M

Adamas Pharmaceuticals, Inc's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 2021.

ADMS Earnings Date & History Chart

ADMS Earnings & Revenue Forecast

ADMS Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $-0.18 $-0.25 $-0.10
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $-1.02 $-1.15 $-0.88
Dec 2022 9 $-0.36 $-0.75 $0.41

ADMS Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.18 $-0.18 $-0.21
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $-1.02 $-1.02 $-1.10
Dec 2022 1 / 0 $-0.36 $-0.36 $-0.28

ADMS Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 8 $27.96M $24.70M $30.83M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 9 $94.16M $90.28M $98.64M
Dec 2022 9 $125.69M $105.00M $150.10M

ADMS Earnings Date & Revenue History

ADMS Earnings History

|
Show More
Show More

ADMS Revenue History

|
Show More
Show More

Adamas Pharmaceuticals, Inc Next Earnings Date & Report

ADMS Next Earnings Date & Report Preview: Sep 2021 (FQ)

ADMS's next earnings date is Wednesday, Nov 3, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 9 analysts, the average EPS estimation for Adamas Pharmaceuticals, Inc's next quarterly earnings is $-0.22, with a low EPS estimation of $-0.28, and a high estimation of $-0.18.

Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.22, the last 2 month trend is $-0.23, and the 3 month trend is $-0.25.

Based on 9 analysts, the average revenue estimation is $24.77M, with a low revenue estimation of $22.00M, and a high estimation of $26.52M.

Adamas Pharmaceuticals, Inc Previous Earnings Dates & Reports

ADMS Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Adamas Pharmaceuticals, Inc's previous earnings date was Aug 9, 2021 for its fiscal quarter ended Jun 30, 2021.

ADMS's earnings per share (EPS) was $-0.27, beating the consensus analysts forecast of $-0.30 by 8.88%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -25.00%, and higher than the same period a year before (Jun 2020) by -27.03%.

Revenues were $21.97M, better than the forecast of $21.97M by 0.00%, up by 13.78% from the previous quarter , and up by 16.91% from the same period last year.

The company reported a net income of $-12.34M.

Free cash flow for the quarter was $-30.27M , compared to $-21.06M last quarter and $-12.21M a year before.

ADMS ended the quarter with $129.71M in total debt, a decrease of -4.42% compared to the previous quarter, and an increase of 0.14% compared to the same quarter a year before.

ADMS Previous Earnings Date & Report Recap: Dec 2020 (FY)

Adamas Pharmaceuticals, Inc's previous annual earnings date was Feb 23, 2021 for its fiscal year ended Dec 31, 2020.

ADMS's earnings per share (EPS) was $-2.02, missing the consensus analysts forecast of $-1.91 by 5.76% , and higher than the previous year's EPS (Dec 2019) by -46.84%.

Revenues were $74.46M, better than the forecast of $74.39M by 0.10%, and up by 36.28% from previous year's revenue.

The company reported a net income of $-57.40M.

Adamas Pharmaceuticals, Inc reported a free cash flow of $-50.71M for its fiscal year, compared to $-80.80M a year ago.

The company ended the fiscal year with $129.96M in total debt, an increase of 1.76% compared to the previous year.